He focuses on tumor targeted molecular imaging and therapy and is interested in the transformation of scientific research. He screened and identified  several tumor-targeted peptides, nanobodies and antibodies (targeting to NRP-1, EDB-FN, KRas, Na+K+ ATPase α1 and BARF1), and translated them into tumor targeted imaging probes and therapeutic drugs.  His  leading transformation project named “The Novel High Precision PET Probes Project” has been completed. He also developed a pan-KRas degrader for treatment of KRas mutant cancers and helped crews to develop the EBV prophylactic and therapeutic mRNA vaccines against EBV associated disease.

Tumor targeted molecular imaging and therapy.

2002-2007 College Degree in Medical Imaging
Southern Medical University, Guangzhou, China

2007-2010 M.M. in Pathophysiology
Southern Medical University, Guangzhou, China

2010-2013 Ph.D. in Oncology
Sun Yat-Sen University, Guangzhou, China

2013-2016 Postdoc in Oncology
Sun Yat-Sen University, Guangzhou, China

2016-2019 Assistant research fellow

2019 to present Associate Professor

1.First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Shi Gao#, Bing Jia#, Guokai Feng#, Chengyan Dong#, Hui Du, Lin Bai, Qian Zhong, Qingjie Ma*, Musheng Zeng*, Fan Wang*. Signal Transduction and Targeted Therapy (2020) 5:147. (IF: 39.3)
2.Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Cong Sun, Yin-Feng Kang1, Yuan-Tao Liu, Xiang-Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yi-Hao Liu, Sui Peng, Guo-Kai Feng*, Zheng Liu* and Mu-Sheng Zeng*. Signal Transduction and Targeted Therapy (2022) 7:42. (IF: 39.3)
3.Rapid Development of SARS-CoV‑2 Spike Protein Receptor-Binding Domain Self Assembled Nanoparticle Vaccine Candidates. Yin-Feng Kang#, Cong Sun#, Zhen Zhuang#, Run-Yu Yuan#, Qing-Bing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiao-Hui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nan-Shan Zhong, Yi-Xin Zeng, Guo-Kai Feng*, Chang-Wen Ke*, Jin-Cun Zhao*, and Mu-Sheng Zeng*.  ACS Nano 2021, 15, 2738−2752. (IF:17.1)
4.Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. Guo-Kai Feng#, Jia-Cong Ye#, Wei-Guang Zhang#, Yan Mei, Chao Zhou, Yi-Tai Xiao, Xin-Ling Li, Wei Fan*, Fan Wang*, Mu-Sheng Zeng*. Journal of Controlled Release 310 (2019) 11–21. (IF:10.8)
5.SPECT and Near-Infrared Fluorescence Imaging of Breast Cancer with a Neuropilin-1-Targeting Peptide. Guo-Kai Feng#, Rong-Bin Liu#, Meng-Qing Zhang#, Xiao-Xuan Ye, Qian Zhong, Yun-Fei Xia, Man-Zhi Li, Jun Wang, Er-Wei Song, Xing Zhang*, Zhao-Zhong Wu*, Mu-Sheng Zeng*. Journal of Controlled Release 192 (2014) 236–242. (IF:10.8)
6.Identification of a sodium pump Na+/K+ ATPase α1-targeted peptide for PET imaging of breast cancer. Qian Wang#, Shi-Bing Li#, Yi-Ying Zhao#, Da-Nian Dai, Hui Du, Yan-Zhu Lin, Jia-Cong Ye, Jing Zhao, Wei Xiao, Yan Mei, Yi-Tai Xiao, Shi-Chu Liu, Yan Li, Yun-Fei Xia, Er-Wei Song, Gang-Hua Tang, Wei-Guang Zhang, Zhi-Jian Li, Xiao-Bin Zheng, De-Hai Cao, Man-Zhi Li, Qian Zhong, Zhong-Ping Chen, Chao-Nan Qian, Wei Fan*, Guo-Kai Feng*, Mu-Sheng Zeng*. Journal of Controlled Release 281 (2018) 178–188. (IF:10.8)
7.An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion. Yan Mei#, Ying-He Li#, Xiao-Chun Yang#, Chao Zhou, Zhi-Jian Li, Xiao-Bin Zheng, Jia-Cong Ye, Cheng Li, Xuan-Hong Zhang, Jian-Min Yuan, Hui-Qiang Huang, Wei Fan, Wei-Guang Zhang*, Mu-Sheng Zeng*, Guo-Kai Feng*. Clinical and Translational Medicine. 2020;10:e157. (IF:10.6)
8.EDB‑FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer. Ruping Li#, Huihui He#, Xinling Li#, Xiaobin Zheng#, Zhijian Li, Hu Zhang, Jiacong Ye, Weiguang Zhang, Chunjing Yu*, Guokai Feng*, Wei Fan*. European Journal of Nuclear Medicine and Molecular Imaging. 2023 Feb 18. (IF:9.1)

Updated by International Office, Sun Yat-sen University Cancer Center